Amylyx spotlights a PhII success in slowing ALS progression. And they’re taking it to the FDA
Just a couple months after pulling in a $30 million Series B round, Amylyx is making another splash with what it hopes are promising data for one of the most notoriously tough R&D fields.
The biotech published the results of its Phase II/III trial in a paper for the New England Journal of Medicine on Wednesday, researching whether its candidate AMX0035 could slow the onset of amyotrophic lateral sclerosis against a standard-of-care-based placebo. Based on the gold-standard of ALS tests, which Amylyx used to measure its primary endpoint, AMX0035 showed a statistically significant reduction in disease progression over about six months.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 148,300+ biopharma pros reading Endpoints daily — and it's free.